ICAD Antibodies

Santa Cruz Biotechnology delivers a wide array of ICAD Antibodies for advanced research in apoptosis and cell death mechanisms. ICAD Antibodies are compatible with multiple techniques, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). ICAD, or Inhibitor of Caspase-Activated DNase, plays a crucial role in regulating apoptosis by inhibiting the activity of caspase-activated DNase, thereby preventing DNA fragmentation during programmed cell death. Understanding the function of ICAD is essential for elucidating the pathways involved in cancer and neurodegenerative diseases, where dysregulation of apoptosis is a key factor. The study of ICAD and its interactions can provide insights into therapeutic targets for enhancing or inhibiting cell death in various pathological conditions. ICAD research has revealed significant connections between abnormal cell death patterns and the progression of various diseases. Investigating ICAD mechanisms has opened new avenues for developing targeted therapies in cancer treatment and neurodegenerative disorders. Santa Cruz Biotechnology monoclonal antibodies for ICAD research support scientists worldwide in advancing our understanding of cell death mechanisms and developing new therapeutic strategies.